Real World Evidence in China: Faricimab Use in Diabetic Macular Edema, Retinal Vein Occlusion, and Neovascular Age-Related Macular Degeneration (The Farseeing Study)

Key facts

Sponsor

Hoffmann-La Roche

Principal Investigator

Clinical Trials

Hoffmann-La Roche

Intervention

Faricimab(drug)

Enrollment

1000 enrolled

Eligibility

18 years · All sexes

Timeline

2024 – 2027

Study locations (30)

• Joint Shantou International Eye Center, Shantou, Guangdong, China
• The First Affiliated Hospital of Henan UN of Science and Technology, Luoyang, Henan, China
• Taihe Hospital of Shiyan, Shiyan, Hubei, China
• Xuzhou No.1 Peoples Hospital, Xuzhou, Jiangsu, China
• Fushun Eye Hospital, Fushun, Liaoning, China
• Panjin Central Hospital, Panjin, Liaoning, China
• The First Hospital of China Medical University, Shenyang, Liaoning, China
• Affiliated Hospital of Shandong Second Medical University, Weifang, Shandong, China
• Shanghai General Hospital, Shanghai, Shanghai Municipality, China
• The First People's Hospital of Chengdu, Chengdu, Sichuan, China
• The First People's Hospital of Kashgar, Kashgar, Xinjiang Uygur, China
• The First People's Hospital of Yunnan Province, Kunming, Yun'nan, China
• Jinhua municipal central hospital, Jinhua, Zhejiang, China
• Peking University People's Hospital, Beijing, China
• Sichuan Provincial People's Hospital, Chengdu, China
• +15 more locations on ClinicalTrials.gov

Collaborators

Shanghai Roche Pharmaceutical Co., Ltd

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Central retinal vein occlusion

Additional recruiting or active studies for the same condition.

• ENROLLING BY INVITATIONPHASE4NCT07456826
  Study Evaluating the Efficacy and Safety of Chloroprocaine HCl Ophthalmic Gel 3% vs Proparacaine Ophthalmic Solution 0.5% Plus Subconjunctival Lidocaine in Patients Undergoing Intravitreal Injections
  Harrow Inc
• ENROLLING BY INVITATIONNANCT07318428
  AI-Assisted Detection of Posterior Segment Diseases: DR, AMD, RVO, and Glaucoma
  Inje University
• RECRUITINGNCT07308639
  DATA-INSIGHT is a Project That Looks at Health Data in Germany to Find Out How Many Patients Suffer From Eye Disease. The Project Also Explores New Ways to Collect and Use Publicly Available Healthcare Information.
  Bayer
• RECRUITINGPHASE2NCT07259928
  Safety and Proof of Concept Study of ANXV (Annexin A5) in Patients With Diabetic Retinopathy or Retinal Vein Occlusion
  Annexin Pharmaceuticals AB
• RECRUITINGEARLY PHASE1NCT04008121
  Feasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium
  MediBeacon
• RECRUITINGNCT07550777
  Serum Cholinesterases, Paraoxonase, and Cardiovascular Risk After Intravitreal Bevacizumab
  Ataturk University
• RECRUITINGPHASE2NCT07205887
  A Dose-masked Study of Intravitreal EYE103 in Participants With NVAMD or Macular Edema Following BRVO
  EyeBiotech Ltd.
• RECRUITINGNANCT07002372
  Effect of Video Viewing on Intravitreal Injection Experience
  Second Affiliated Hospital, School of Medicine, Zhejiang University

See all trials for Central retinal vein occlusion →